Literature DB >> 33009986

Construction and immune protection evaluation of recombinant virus expressing Newcastle disease virus F protein by the largest intergenic region of fowlpox virus NX10.

Yan Zhao1,2, Zongxi Han2, Xiaocai Zhang2, Xuemei Zhang2, Junfeng Sun2, Deying Ma3, Shengwang Liu4.   

Abstract

Fowlpox virus (FPV) is used as a vaccine vector to prevent diseases in poultry and mammals. The insertion site is considered as one of the main factors influencing foreign gene expression. Therefore, the identification of insertion sites that can stably and efficiently express foreign genes is crucial for the construction of recombinant vaccines. In this study, we found that the insertion of foreign genes into ORF054 and the ORF161/ORF162 intergenic region of the FPV genome did not affect replication, and that the foreign genes inserted into the intergenic region were more efficiently expressed than when they were inserted into a gene. Based on these results, the recombinant virus rFPVNX10-NDV F-E was constructed and immune protection against virulent FPV and Newcastle disease virus (NDV) was evaluated. Tests for anti-FPV antibodies in the vaccinated chickens were positive within 14 days post-vaccination. After challenge with FPV102, no clinical signs of FP were observed in vaccinated chickens, as compared to that in the control group (unvaccinated), which showed 100% morbidity. Low levels of NDV-specific neutralizing antibodies were detected in vaccinated chickens before challenge. After challenge with NDV ck/CH/LHLJ/01/06, all control chickens died within 4 days post-challenge, whereas 5/15 vaccinated chickens died between 4 and 12 days post-challenge. Vaccination provided an immune protection rate of 66.7%, whereas the control group showed 100% mortality. These results indicate that the ORF161/ORF162 intergenic region of FPVNX10 can be used as a recombination site for foreign gene expression in vivo and in vitro.

Entities:  

Keywords:  Enhanced green fluorescent protein; Fowlpox virus NX10 strain; Gaussia luciferase; Immune protection; Intergenic region; Non-essential sites

Mesh:

Substances:

Year:  2020        PMID: 33009986     DOI: 10.1007/s11262-020-01799-5

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  40 in total

1.  The L1 protein of human papilloma virus 16 expressed by a fowlpox virus recombinant can assemble into virus-like particles in mammalian cell lines but elicits a non-neutralising humoral response.

Authors:  Massimiliano Bissa; Carlo Zanotto; Sole Pacchioni; Luca Volonté; Aldo Venuti; David Lembo; Carlo De Giuli Morghen; Antonia Radaelli
Journal:  Antiviral Res       Date:  2015-02-07       Impact factor: 5.970

2.  DNA vaccine prime and recombinant FPV vaccine boost: an important candidate immunization strategy to control bluetongue virus type 1.

Authors:  Junping Li; Tao Yang; Qingyuan Xu; Encheng Sun; Yufei Feng; Shuang Lv; Qin Zhang; Haixiu Wang; Donglai Wu
Journal:  Appl Microbiol Biotechnol       Date:  2015-06-06       Impact factor: 4.813

Review 3.  Enhancing poxvirus vectors vaccine immunogenicity.

Authors:  Juan García-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

4.  Avian host spectrum of avipoxviruses.

Authors:  A L Bolte; J Meurer; E F Kaleta
Journal:  Avian Pathol       Date:  1999-10       Impact factor: 3.378

5.  Protection of chickens against infectious bronchitis by a recombinant fowlpox virus co-expressing IBV-S1 and chicken IFNgamma.

Authors:  Yun-Feng Wang; Yong-Ke Sun; Zhan-Cheng Tian; Xing-Ming Shi; Guang-Zhi Tong; Sheng-Wang Liu; Hai-Dong Zhi; Xian-Gang Kong; Mei Wang
Journal:  Vaccine       Date:  2009-09-26       Impact factor: 3.641

6.  Protection of chickens from infectious laryngotracheitis with a recombinant fowlpox virus expressing glycoprotein B of infectious laryngotracheitis virus.

Authors:  G Z Tong; S J Zhang; L Wang; H J Qiu; Y F Wang; M Wang
Journal:  Avian Pathol       Date:  2001-04       Impact factor: 3.378

7.  GFP co-expression reduces the A33R gene expression driven by a fowlpox vector in replication permissive and non-permissive cell lines.

Authors:  Massimiliano Bissa; Sole Maria Pacchioni; Carlo Zanotto; Carlo De Giuli Morghen; Antonia Radaelli
Journal:  J Virol Methods       Date:  2012-09-18       Impact factor: 2.014

8.  Virus taxonomy: the database of the International Committee on Taxonomy of Viruses (ICTV).

Authors:  Elliot J Lefkowitz; Donald M Dempsey; Robert Curtis Hendrickson; Richard J Orton; Stuart G Siddell; Donald B Smith
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

9.  Evaluation of recombinant fowlpox virus expressing infectious bronchitis virus S1 gene and chicken interferon-γ gene for immune protection against heterologous strains.

Authors:  Xing-Ming Shi; Yan Zhao; Hong-Bo Gao; Zhang Jing; Mei Wang; Hong-Yu Cui; Gang-Zhi Tong; Yun-Feng Wang
Journal:  Vaccine       Date:  2011-01-07       Impact factor: 3.641

10.  A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers.

Authors:  Massimiliano Bissa; Elena Illiano; Sole Pacchioni; Francesca Paolini; Carlo Zanotto; Carlo De Giuli Morghen; Silvia Massa; Rosella Franconi; Antonia Radaelli; Aldo Venuti
Journal:  J Transl Med       Date:  2015-03-05       Impact factor: 5.531

View more
  2 in total

1.  Genomic characteristics and pathogenicity of a new recombinant strain of porcine reproductive and respiratory syndrome virus.

Authors:  Yang Li; Gaoxiao Xu; Xingqian Du; Lele Xu; Zhiqian Ma; Zhiwei Li; Yingtong Feng; Dian Jiao; Wenping Guo; Shuqi Xiao
Journal:  Arch Virol       Date:  2021-01-01       Impact factor: 2.574

2.  Responses of Passiflora spp. to cowpea aphid-borne mosaic virus reveal infection in asymptomatic plants and new species with probable immunity.

Authors:  Zanon Santana Gonçalves; Onildo Nunes Jesus; Lucas Kennedy Silva Lima; Ronan Xavier Corrêa
Journal:  Arch Virol       Date:  2021-06-16       Impact factor: 2.574

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.